HomeENGLISH MAGAZINEVarian(t)bility spikes: either english and brasilian coronavirus jump faster than primeval

Varian(t)bility spikes: either english and brasilian coronavirus jump faster than primeval

SARS-CoV-2 has a slower mutation rate compared to other RNA viruses.

However, because of the coronavirus disease 2019 (COVID-19) pandemic and high transmissibility, the virus has acquired several mutations, with the D614G currently being the predominant variant globally. Emerging mutations in the virus may affect transmission, infectivity, and our immunity to them. This is why some have been termed variants of concern (VOCs). Three VOCs emerged starting late-2020, having several mutations in the genome. The variant from the United Kingdom B.1.1.7, has 17 mutations, including N501Y, which makes it more transmissible than other circulating variants. This variant has now become the predominant strain in the UK and Europe. The two other VOCs detected first in South Africa, and Brazil have the E484K and K417N/K417T mutations in addition to E484K. Studies have suggested that the E484K mutation may be resistant to antibody neutralization, reducing vaccine efficacy. Another variant was reported in January 2021 in California with the L452R mutation.

This variant is more transmissible than circulating strains but slightly less transmissible than the new N501Y variant and moderately resistant to antibodies in convalescent sera and mRNA vaccines. The researchers sequenced 2,172 viral genomes in 44 California counties from samples that tested positive for SARS-CoV-2. The new variant, called 20C/L452R or B.1.427/B.1.429, was seen in about 21% of the genomes. This genome grew from 0% in September 2020 to more than 50% of the sequenced genomes in January 2021, a rapid increase in the number of cases compared to the other circulating variants. Further analysis revealed two different lineages in clade 20C, B.1.427 and B.1.429. Both have three mutations in the spike protein (S13I, W152C, and L452R), another coding mutation in the orf1b protein, and two non-coding mutations. Four more mutations were specific to B.1.427, and three others were specific to B.1.429. These lineages likely diverged in June-July 2020.

Although the sudden appearance of several new mutations in a new virus variant is not unexpected, the evolutionary mechanism remains unknown. The divergence could have occurred by accelerated quasispecies evolution in patients infected for a long time. The median PCR cycle threshold value (Ct) associated with the new variants was much lower than that of the non-variants. The viral RNA in swab samples is about 2-fold higher in the new variants. To understand how the L452R variant affects viral entry, the team used pseudoviruses with different mutations and infected 293T cells expressing the angiotensin-converting enzyme 2 (ACE2) receptor and TMPRSS2 protein and human airway lung organoids. They found viruses with the L452R mutation had up to 22.5-fold and 14.7-fold higher entry in 293T and the organoids, respectively, slightly lower than viruses with the N501Y mutation. So, one question is if the L452R variant would remain to be the predominant strain in California or if it would be replaced by the N501Y variant (B.1.1.7).

The team also tested the effect of convalescent plasma and samples from vaccinated individuals in neutralizing the variant virus. About 88% of the convalescent sera and 55% of the Pfizer or Moderna vaccine recipients showed reduced titers to the B.1.429 lineage in plaque reduction neutralization tests. Neutralization antibody response tests showed reduced neutralization antibody titers for the B.1.427 lineage. Thus, the new variants were resistant to antibodies from prior infection by about 4 to 6-fold and to vaccination by about 2-fold. This suggests immune selection pressure could be partly responsible for the mutations. However, mRNA vaccines seem to provide robust antibodies in response to these variants selected under immune pressure. The results suggest that the variants B.1.427 and B.1.429 require continued investigation and monitoring for potential future COVID-19 surges and reduced vaccine efficacy.

Although it is likely that these variants emerged as early as May 2020, they were not identified in the United States until July and September 2020 for the B.1.429 and B.1.427 lineages, respectively. This is probably because of poor genomic sequencing of circulating viruses. The first public disclosure of this variant was done only in January 2021, and by then, the variants had become the predominant strains in several California counties and had spread to other states. Earlier identification could have allowed better contact tracing and timely investigation of its significance. Thsi could derive from the decision of CDCs in February 17 to have labeled this variant “non-concerning”.

  • edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -